Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Roxithromycin passage in the cervix mucus].

M Mounier1, P Renaudie, J Baudet

  • 1Service de Bactériologie-Virologie, Centre Hospitalier Universitaire Dupuytren, Limoges.

Pathologie-Biologie
|May 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

[Radiation-oncology horizon 2030: From microbiota to plasma laser].

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2020
Same author

[New concepts of medical consultation in oncology].

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2020
Same author

[Immunity and antiviral vaccinations. Example: the respiratory mucosa].

Antibiotiques (Paris, France : 1999)·2020
Same author

Meningococcal C vaccine coverage in France in infants, children, and adolescents.

Medecine et maladies infectieuses·2019
Same journal

Pathologie-biologie·2020
Same journal

Antibacterial and antibiofilm activities of Laurus nobilis L. essential oil against Staphylococcus aureus strains associated with oral infections.

Pathologie-biologie·2015
Same journal

[Not Available].

Pathologie-biologie·2015
Same journal

Oxidative damage and histopathological changes in lung of rat chronically exposed to nicotine alone or associated to ethanol.

Pathologie-biologie·2015
Same journal

Biological diagnosis of diabetes mellitus.

Pathologie-biologie·2015
Same journal

Association of CagPAI integrity with severeness of Helicobacter pylori infection in patients with gastritis.

Pathologie-biologie·2015
See all related articles

Roxithromycin levels in cervical mucus were measured in women receiving standard doses. Concentrations achieved are effective against common genital pathogens but may be insufficient for Neisseria gonorrhoeae.

Area of Science:

  • Pharmacokinetics and Drug Distribution
  • Gynecological Infections
  • Antimicrobial Therapy

Context:

  • Studied roxithromycin diffusion in cervical mucus of healthy women undergoing IUD insertion.
  • Participants received a standard 7-day course of roxithromycin (150 mg twice daily).
  • Cervical mucus samples collected 1-12 hours post-last dose.

Purpose:

  • To determine roxithromycin concentrations in cervical mucus.
  • To assess the potential efficacy against common genital pathogens based on Minimum Inhibitory Concentrations (MICs).

Summary:

  • Roxithromycin levels in cervical mucus ranged from 0.45 to 2.07 mg/l (median 0.80 mg/l).
  • Acid alpha-1-glycoprotein levels remained stable (median 0.19 mg/l).
  • Observed concentrations exceeded MICs for C. trachomatis, G. vaginalis, H. ducreyi, and U. urealyticum, but not for N. gonorrhoeae and M. hominis.

Related Experiment Videos

Impact:

  • Provides crucial pharmacokinetic data for roxithromycin in the female reproductive tract.
  • Suggests potential therapeutic utility against specific bacterial vaginosis and sexually transmitted infection pathogens.
  • Highlights limitations in achieving effective concentrations against N. gonorrhoeae and M. hominis with standard dosing.